跳至主要内容
临床试验/NCT00466635
NCT00466635终止3 期

An Open-label Study to Assess the Safety, Efficacy and Absorption of Exodif™ (Tolevamer Potassium Sodium) Tablets in Patients With Clostridium Difficile-Associated Diarrhea

Genzyme, a Sanofi Company13 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2007年4月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
终止
发起方
入组人数
65
试验地点
13
主要终点
Safety

研究概览

简要总结

Approximately 65 patients will be entered into this study taking place in North America. The aim of this study is to evaluate the safety, efficacy and absorption of an investigational drug in patients with C. difficile-associated diarrhea (CDAD). All study related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is 6 weeks.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The presence of CDAD at the time of enrollment
  • Negative serum pregnancy test (HCG) for women of childbearing potential.

排除标准

  • Any contraindication to oral / enteral therapy including fulminant C. difficile disease.
  • Any acutely life-threatening medical conditions.
  • Acute or chronic diarrhea of other cause.

结局指标

主要结局

Safety

Clinical Success

次要结局

  • The extent of tolevamer absorption

研究者

发起方
Genzyme, a Sanofi Company
申办方类型
Industry

研究点 (13)

Loading locations...

相似试验